Foghorn Therapeutics Future Growth
Future criteria checks 2/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Foghorn Therapeutics.
Key information
7.4%
Earnings growth rate
16.1%
EPS growth rate
| Biotechs earnings growth | 22.4% |
| Revenue growth rate | 50.0% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 09 May 2023 |
Recent future growth updates
Recent updates
Foghorn Therapeutics: Selling For Less Than Cash Value
Oct 10Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286
Aug 23Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M
Aug 09Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity
Jun 02We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely
Apr 13
Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?
Feb 27Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 40 | -166 | -174 | N/A | 4 |
| 12/31/2024 | 35 | -147 | -146 | N/A | 7 |
| 12/31/2023 | 23 | -131 | -127 | N/A | 7 |
| 3/31/2020 | N/A | -54 | -48 | -47 | N/A |
| 12/31/2019 | N/A | -51 | -47 | -46 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FHTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FHTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FHTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FHTX's revenue (50% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: FHTX's revenue (50% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FHTX's Return on Equity is forecast to be high in 3 years time